Loading company…
ZGene A/S develops ZAS™, a genetic activator that makes cancer drugs more potent by targeting cancer cells.
Founded in 2001 and based in Horsholm, Denmark, ZGene A/S develops ZAS™, a genetic activator intended to heighten the potency of cancer drugs. ZAS is designed to bind to cancer cells so that drugs can destroy them in their activated state.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in